SANOFI has announced the US$11.6b acquisition of Bioverative, a biopharmaceutical company focused on haemophilia and other rare blood disorders therapies, including Eloctate and Alprolix, both of which are marketed in Australia, Japan & North America.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jan 18
